Get the Stockscreener App
10.15
0.30%
0.03
After Hours:
10.05
-0.10
-0.99%
Cybin Inc stock is traded at $10.15, with a volume of 57,342.
It is up +0.30% in the last 24 hours and up +9.73% over the past month.
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.
See More
Previous Close:
$10.12
Open:
$9.96
24h Volume:
57,342
Relative Volume:
0.32
Market Cap:
$201.18M
Revenue:
-
Net Income/Loss:
$-52.07M
P/E Ratio:
-52.35
EPS:
-0.1939
Net Cash Flow:
$-44.93M
1W Performance:
-3.33%
1M Performance:
+9.73%
6M Performance:
-23.68%
1Y Performance:
-55.15%
1-Day Range:
$9.94
$10.18
1-Week Range:
$9.62
$10.50
52-Week Range:
$6.50
$22.31
Cybin Inc Stock (CYBN) Company Profile
Name
Cybin Inc
Sector
Industry
Phone
908 764 8385
Address
100 King Street West, Suite 5600, Toronto
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Cybin Inc Stock (CYBN) Latest News
Cybin, Inc.Why Compass Pathways Is No Compass for Cybin's Progression Prospects - Smartkarma
PDS Planning Inc Has $2.38 Million Stock Holdings in Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin Inc: Another High-Risk Psychedelics Play (NYSE:CYBN) - Seeking Alpha
Cybin to Participate at the 2024 Milken Institute Future of Health Summit - BioSpace
Cybin to Highlight Innovations at Health Summit - TipRanks
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
(CYBN) Pivots Trading Plans and Risk Controls - Stock Traders Daily
EXCLUSIVE: Neuropsychiatry-Focused Cybin Secures First US Composition of Matter Patent For Preclinical CYB005 Phenethylamines Program - MSN
Cybin secures patent for CNS disorder treatment candidates - Investing.com
Cybin announces grant of patent in support of CYB005 phenethylamines program - TipRanks
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program - Yahoo Finance UK
$DRUG 5,900% Weekly Surge Turns Attention. Cybin ($CYBN) Rallying 23% This Week In Anticipation For Major Milestones - FinanceFeeds
Sanctuary Advisors LLC Makes New Investment in Cybin Inc. (NYSE:CYBN) - MarketBeat
Cybin (NYSE:CYBN) Trading Down 7.4%What's Next? - MarketBeat
Cybin (NYSE:CYBN) Stock Price Up 9.7%What's Next? - MarketBeat
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor + - Seeking Alpha
(CYBN) Trading Signals - Stock Traders Daily
Cybin: Top Value Psychedelic Stock (NYSE:CYBN) - Seeking Alpha
Cybin (NYSE:CYBN) Shares Gap DownWhat's Next? - MarketBeat
Cybin (OTCMKTS:CYBN) Trading 1.5% HigherHere's What Happened - MarketBeat
Cybin (NYSE:CYBN) Shares Up 5.4%Still a Buy? - MarketBeat
(CYBN) Investment Analysis and Advice - Stock Traders Daily
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) CEO to Participate in Upcoming Water Tower Research Fireside Chat - MSN
Cybin Inc. CEO to Speak at Research Event - TipRanks
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024 - StockTitan
Cybin (NYSE:CYBN) Trading Down 4.8% - MarketBeat
Cybin gears up for Phase 3 trial in depression treatment By Investing.com - Investing.com South Africa
Cybin gears up for Phase 3 trial in depression treatment - Investing.com
Cybin Gears Up for Global Phase 3 Depression Trial - TipRanks
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program - Yahoo Finance
Cybin (NYSE:CYBN) Shares Gap Down to $9.88 - MarketBeat
Water Tower Research Publishes Initiation of Coverage - GlobeNewswire
Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics” - Yahoo Finance
When the Price of (CYBN) Talks, People Listen - Stock Traders Daily
Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World
Cybin Inc. (NYSEAMERICAN:CYBN) Sees Large Decline in Short Interest - Defense World
Cybin Joins Prestigious Neuropsychiatry Summit - TipRanks
Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit - Business Wire
Ice Cube Says He's 'Never' Been to a Diddy Party After Rapper's Arrest - Us Weekly
Tilray (NASDAQ:TLRY) Shares Down 1.2% - Defense World
Cybin (NYSE:CYBN) Sees Strong Trading Volume - MarketBeat
Cybin (NYSEAMERICAN:CYBN) Sees Strong Trading Volume - Defense World
Cybin (NYSEAMERICAN:CYBN) Sees Unusually-High Trading Volume - MarketBeat
CYBN’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
‘It’s a little kinky’: Diddy shares the key elements of a ‘freak off’ in this old clip - Yahoo Entertainment
Canaccord Genuity Group Lowers Cybin (NYSE:CYBN) Price Target to $96.00 - MarketBeat
Sean ‘Diddy’ Combs Describes His Parties amid ‘Freak Offs’ Allegations in Resurfaced ‘Conan’ Interview: ‘You Need Locks on the Doors’ - Breitbart
Ice Cube Assures Fans He’s Never Been To A Diddy Party Amid “Freak-Off” Accusations - Vibe
Cybin shares target cut by Canaccord, maintains Buy rating - Investing.com
Cybin Inc (CYBN)’s stock chart: A technical perspective - US Post News
Compass Pathways to Participate in Cowen Psychedelics and Novel Mechanisms in Neuropsychiatry Summit - NTB Kommunikasjon
Cybin Inc Stock (CYBN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Cap:
|
Volume (24h):